Literature DB >> 8506883

Screening elderly populations for cobalamin (vitamin B12) deficiency using the urinary methylmalonic acid assay by gas chromatography mass spectrometry.

E J Norman1, J A Morrison.   

Abstract

PURPOSE: This study assesses the value of the urinary methylmalonic acid (MMA) assay by gas chromatography mass spectrometry as a screening procedure for detection of cobalamin (Cbl) deficiency and estimates the prevalence of undetected Cbl deficiency in elderly populations. SUBJECTS AND METHODS: A total of 809 elderly individuals over age 65 were screened using random spot urine specimens from 4 different sites: a health fair, retirement apartments, a hospital-based elderly assessment center, and a nursing home. Follow-up tests included serum total Cbl, serum MMA, and normalization of urinary and serum MMA levels with Cbl intramuscular (IM) therapy.
RESULTS: The prevalence of elevated urinary MMA varied across population groups, from 3.0% in elderly visiting a health fair to 5.1% in elderly residing in retirement apartments. Follow-up on 35 of 36 subjects with elevated urinary MMA levels showed that 18 had low serum total Cbl (less than 180 pg/mL at Hospital 1 or less than 200 pg/mL at Hospital 2), 12 had low-normal Cbl (180 or 200 pg/mL to 350 pg/mL), and 5 had normal Cbl. Of the 12 subjects with low-normal Cbl on retesting, further assessment was performed in 7, and all 7 of these subjects had evidence of Cbl deficiency. Cbl IM therapy was initiated for 23 subjects; 16 were seen for follow-up and all had normal urinary MMA.
CONCLUSION: The relatively high prevalence of undetected Cbl deficiency identified in the seniors warrants additional studies of elderly populations. The sensitivity, convenience, and noninvasive nature of the urinary MMA assay by gas chromatography mass spectrometry make it a practical screening test.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8506883     DOI: 10.1016/0002-9343(93)90209-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  5 in total

1.  Utility of measuring vitamin B12 and its active fraction, holotranscobalamin, in neurological vitamin B12 deficiency syndromes.

Authors:  Wiebke Schrempf; Marco Eulitz; Volker Neumeister; Gabriele Siegert; Rainer Koch; Heinz Reichmann; Alexander Storch
Journal:  J Neurol       Date:  2010-10-02       Impact factor: 4.849

2.  Risk of dementia in elderly patients with the use of proton pump inhibitors.

Authors:  Britta Haenisch; Klaus von Holt; Birgitt Wiese; Jana Prokein; Carolin Lange; Annette Ernst; Christian Brettschneider; Hans-Helmut König; Jochen Werle; Siegfried Weyerer; Melanie Luppa; Steffi G Riedel-Heller; Angela Fuchs; Michael Pentzek; Dagmar Weeg; Horst Bickel; Karl Broich; Frank Jessen; Wolfgang Maier; Martin Scherer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-10-24       Impact factor: 5.270

3.  A new 13C breath test to detect vitamin B12 deficiency: a prevalent and poorly diagnosed health problem.

Authors:  David A Wagner; Richard Schatz; Richard Coston; Cheryl Curington; Daniel Bolt; Phillip P Toskes
Journal:  J Breath Res       Date:  2011-06-23       Impact factor: 3.262

4.  Orthostatic hypotension as a manifestation of vitamin B12 deficiency.

Authors:  Leila Ganjehei; Ali Massumi; Mehdi Razavi; James M Wilson
Journal:  Tex Heart Inst J       Date:  2012

5.  Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes.

Authors:  Jiwoon Kim; Chul Woo Ahn; Sungsoon Fang; Hye Sun Lee; Jong Suk Park
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.